iPSC Clinical Trials Enter a Full Acceleration Phase | The Golden Era of Regenerative Medicine

According to the latest 2025 report from Cell Stem Cell, as of the end of 2024, there are 115 ongoing pluripotent stem cell (hPSC) clinical trials worldwide, a significant proportion of which are based on iPSC (induced pluripotent stem cell) technology.

🔬 What is iPSC Technology?

iPSC technology uses cellular reprogramming to revert mature somatic cells back to a youthful state, restoring their ability to regenerate multiple tissues and organs. This breakthrough was recognized with the 2012 Nobel Prize.

🔬 Latest Progress in iPSC Clinical Therapies (2025)

☑️ Cardiovascular disease: iPSC-derived cardiac cell sheets and mini-hearts are being developed, potentially reducing the need for heart transplants
☑️ Diabetes: transplantation of iPSC-derived pancreatic cells has successfully reversed Type 1 diabetes
☑️ Cancer: CAR-iNK gene-edited cell therapy has shown up to a 50% complete response rate in clinical trials for blood cancers and solid tumors
☑️ Ophthalmology: iPSC-derived retinal and corneal cells are being developed to help restore vision
☑️ Parkinson’s disease: iPSC-derived dopamine neurons are improving motor function
☑️ Kidney disease: iPSC-derived renal progenitor cells may restore kidney function and suppress fibrosis, offering a potential alternative to dialysis
☑️ Dentistry: regeneration of dental pulp and even whole teeth
☑️ Burn injuries: reconstruction of skin tissue to support severe injury repair

🔬 Banking iPSCs: A Proactive Strategy for Lifelong Health

✅ Future disease treatment: Reserve healthy cells in advance for personalized therapies in cardiovascular disease, degenerative disorders, and more
✅ Regenerative and anti-aging potential: Serve as a foundation for rejuvenation and repair therapies, helping the body regain peak condition
✅ Health security: Build long-term health assets for yourself and your family, extending care and well-being into the future

Reference: https://www.cell.com/cell-stem-cell/fulltext/S1934-5909(24)00445-4